Adage Capital Partners
AMLX icon

Adage Capital Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Adage Capital Partners’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49.5M Buy
3,560,764
+783,709
+28% +$11M 0.08% 251
2025
Q4 		$33.5M Sell
2,777,055
-4,039,773
-59% -$54.9M 0.05% 342
2025
Q3 		$92.6M Sell
6,816,828
-1,983,172
-23% -$18.7M 0.15% 140
2025
Q2 		$56.4M Buy
8,800,000
+3,102,395
+54% +$15.1M 0.1% 206
2025
Q1 		$20.2M Buy
+5,697,605
New +$20.3M 0.04% 411
2023
Q4 		– Sell
-1,700,200
Closed -$31.1M – 853
2023
Q3 		$31.1M Buy
1,700,200
+932,000
+121% +$19.7M 0.07% 289
2023
Q2 		$16.6M Sell
768,200
-239,136
-24% -$6.46M 0.04% 463
2023
Q1 		$29.6M Sell
1,007,336
-901,865
-47% -$31.3M 0.07% 322
2022
Q4 		$70.5M Buy
1,909,201
+559,201
+41% +$19.8M 0.17% 151
2022
Q3 		$38M Buy
1,350,000
+1,150,000
+575% +$28.7M 0.09% 230
2022
Q2 		$3.85M Buy
200,000
+162,800
+438% +$1.93M 0.01% 830
2022
Q1 		$478K Buy
+37,200
New +$840K ﹤0.01% 956

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Adage Capital Partners's AMLX Position: Q1 2026 in Review

Adage Capital Partners increased its Amylyx Pharmaceuticals (AMLX) stake by 28% in Q1 2026, buying an estimated $11M and bringing the position to 3,560,764 shares worth $49.5M. The position accounts for 0.08% of the portfolio, ranked #251.

Adage Capital Partners first reported a position in AMLX in Q1 2022 and has held it in 12 quarters since. The position peaked at $92.6M in Q3 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Adage Capital Partners held 3,560,764 shares of Amylyx Pharmaceuticals worth $49.5M as of Q1 2026.
  • Adage Capital Partners bought 783,709 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $11M.
  • Amylyx Pharmaceuticals made up 0.08% of Adage Capital Partners's portfolio in Q1 2026, its #251 holding.
  • Adage Capital Partners first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 12 quarters since.
  • Adage Capital Partners's Amylyx Pharmaceuticals position peaked at $92.6M in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.